News | Cardiovascular Surgery | February 18, 2022

Evonik invests in U.S. start-up offering medical device to improve patient recovery after open-chest surgery

CircumFix’s innovative orthopedic device closes and stabilizes the sternum after surgery

Evonik Venture Capital has invested in CircumFix Solutions, a Tennessee-based start-up that has developed a new sternal closure device to improve patient recovery after open chest surgery. The patented orthopedic device, made of a high-performance polymer from Evonik, closes and holds the sternum securely together after surgery. 

CircumFix’s medical device is composed of a slender chest plate placed on the sternum and held in place by fasteners that encircle the sternum and are affixed to the plate.


January 18, 2022 – Evonik Venture Capital has invested in CircumFix Solutions, a Tennessee-based start-up that has developed a new sternal closure device to improve patient recovery after open chest surgery. The patented orthopedic device, made of a high-performance polymer from Evonik, closes and holds the sternum securely together after surgery. 

“We are seeing a revolution in implantable medical devices with the shift from metal to high-performance polymers and this investment supports that shift,” said Bernhard Mohr, head of Evonik Venture Capital. “Patients and doctors can benefit enormously from a technology that is safe, reliable and enhances recovery.”

CircumFix’s medical device is composed of a slender chest plate placed on the sternum and held in place by fasteners that encircle the sternum and are affixed to the plate. The construct allows for even “load sharing” of bone and device and restricts motion, which increases stability and reduces pain. Surgeons can close the sternum faster and more easily than with traditional devices. Should a further operation be needed the device can be quickly reopened and closed again. It is safe and comfortable as a permanent implant. In comparison to some metal devices currently on the market, bones and tissue aren’t damaged.

The Evonik material used in the closure device is an implant grade polyether ether ketone, or PEEK. The material is biocompatible - not harmful or toxic to living tissue – and bioinert – it doesn’t initiate a response from the body. These properties as well as being hydrophobic – repelling water – significantly reduce the chance of infection. Being made from PEEK polymer means that the device is transparent to x-rays and therefore doesn’t interfere with post-surgical diagnostics. 

“The investment will deepen our relationships across the medical technology industry and with engineering companies,” said Marc Knebel, head of Medical Systems at Evonik. “At the same time, we can reach U.S. clinical experts in orthopedics, many of whom are less aware of PEEK as an alternative to titanium and stainless steel.”

The U.S. sternal closure device market was estimated at $1.4 billion for 2021 with more than 700,000 procedures performed per year. The market is expected to grow at a compound annual growth rate of 5 percent reaching $1.9 billion by 2026.

The investment will allow Evonik to build on expertise already acquired in implant-grade high-performance polymers. PEEK is already used in spine, skull, jaw and face surgery as well as orthopedics and has high potential to be used in other medical applications. 

Circumfix Solution, Inc. founders Louis Houff and Ken Richardson have more than 50 years combined experience in orthopedic sales, marketing, product development and senior leadership roles. They founded the company in 2020 recognizing the need for improved sternum closure techniques and materials. Houff first conceived of the novel bone fixation and healing concept in 2012 and received his first patent in 2017.

“We are making great progress towards the goal of improving patient recovery,” said Houff, who is also chief executive officer of CircumFix. “With support from Evonik, we will be able to further drive business development forward.”

Evonik markets its high-performance polymer Polyether ether ketone under the name VESTAKEEP.

For more information: https://circumfix.com/


Related Content

News | Cardiovascular Surgery

June 3, 2024 — Morristown Medical Center’s Gagnon Cardiovascular Institute’s structural heart program recently reported ...

Home June 03, 2024
Home
News | Cardiovascular Surgery

May 16, 2024 — A recent publication in the American Heart Association Circulation highlights a comprehensive ...

Home May 16, 2024
Home
News | Cardiovascular Surgery

April 30, 2024 — The expanding use of transcatheter technologies has changed the landscape in the treatment of valvular ...

Home April 30, 2024
Home
News | Cardiovascular Surgery

April 23, 2024 — Medtronic plc, a global leader in healthcare technology, today announced the launch of its latest ...

Home April 23, 2024
Home
News | Cardiovascular Surgery

March 20, 2024 — PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable ...

Home March 20, 2024
Home
News | Cardiovascular Surgery

February 26, 2024 — Hackensack Meridian Jersey Shore University Medical Center and Hackensack University Medical Center ...

Home February 26, 2024
Home
Feature | Cardiovascular Surgery

The DAIC team has learned of the passing of Alain Cribier, MD, FACC, heralded as the man who pioneered the first ...

Home February 23, 2024
Home
News | Cardiovascular Surgery

January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under ...

Home January 29, 2024
Home
News | Cardiovascular Surgery

January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication ...

Home January 11, 2024
Home
News | Cardiovascular Surgery

December 20, 2023 — The Smidt Heart Institute at Cedars-Sinai has opened an Aortic Surveillance Clinic for the ...

Home December 20, 2023
Home
Subscribe Now